Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **human airway epithelial cell** refers to any of several specialized cell types that line the airways from the nasal passages through bronchioles. This pseudostratified layer includes ciliated cells that move mucus out of the lungs; goblet/secretory cells that produce mucus; basal stem/progenitor cells responsible for regeneration after injury; and club/Clara cells with secretory functions in distal airways[1][2][3][5]. Together they form an essential physical barrier protecting against inhaled pathogens and particulates while maintaining mucociliary clearance—a process critical to lung health. These epithelial layers also play key roles in innate immunity by secreting antimicrobial peptides and modulating inflammation through interactions with immune system components such as dendritic and T/B lymphocytes[4]. Dysfunction or damage to these cellular populations contributes directly to diseases like asthma, COPD, cystic fibrosis, chronic bronchitis, respiratory infections—and can serve as sites of origin for certain lung cancers. Note: "Human airway epithelial cell" is *not* a single molecule/receptor/enzyme/transporter but rather describes an entire class/population of differentiated human somatic cells forming tissue barriers in airways. It should not be considered a canonical drug target per se—though individual proteins expressed by these cells may be valid targets themselves. No specific drugs target "human airway epithelial cells" as a class; rather, drugs may affect or be delivered to the airway epithelium. Mechanism of action is not applicable as this is a heterogeneous population of cells rather than a molecular target. Some markers are used to identify subtypes within the population but not for patient selection in the sense used for molecular drug targets. Examples include cytokeratins for basal cells or mucin genes for goblet cells.[2][3] Safety concerns are not applicable as this is not a direct therapeutic target. However, therapies targeting the airway epithelium must consider risks such as impaired barrier function or altered immune response.
Not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human airway epithelial cell.